Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (opent nieuw venster)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Bron‎: Ann Intern Med 2008;148(12):939-55.

Geïndexeerd‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (opent nieuw venster)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (opent nieuw venster)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Bron‎: Am J Hematol 2000;64(1):26-31.

Geïndexeerd‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (opent nieuw venster)

Hydroxyurea for the treatment of sickle cell anemia. (opent nieuw venster)

Platt OS.

Bron‎: N Engl J Med 2008;358(13):1362-9.

Geïndexeerd‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (opent nieuw venster)

Clinical effectiveness of decitabine in severe sickle cell disease. (opent nieuw venster)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Bron‎: Br J Haematol 2008;141(1):126-9.

Geïndexeerd‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (opent nieuw venster)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (opent nieuw venster)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Bron‎: Blood 2010;115(12):2354-63.

Geïndexeerd‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (opent nieuw venster)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (opent nieuw venster)

Hirst C, Owusu-Ofori S.

Bron‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Geïndexeerd‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (opent nieuw venster)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (opent nieuw venster)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Bron‎: Lancet Haematol 2021;8(5):e323-33.

Geïndexeerd‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (opent nieuw venster)

Sickle cell disease. (opent nieuw venster)

Meremikwu MM, Okomo U.

Bron‎: BMJ Clin Evid 2011;02:2402.

Geïndexeerd‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (opent nieuw venster)

A phase 3 trial of l-glutamine in sickle cell disease. (opent nieuw venster)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Bron‎: N Engl J Med 2018;379(3):226-35.

Geïndexeerd‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (opent nieuw venster)

Malaria chemoprophylaxis in sickle cell disease. (opent nieuw venster)

Oniyangi O, Omari AA.

Bron‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Geïndexeerd‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (opent nieuw venster)